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Research
Because of their repellent properties and low 
surface tension, fluorochemicals have been 
used extensively for more than half a century 
in various commercial applications, includ-
ing carpets, textiles, personal care products, 
leveling and wetting agents and in food-
contact materials (D’eon and Mabury 2011). 
Use and production of fluorochemicals 
has resulted in the environmental presence 
of perfluoroalkyl acids (PFAAs) (Giesy and 
Kannan 2002), which are highly persistent 
compounds consisting of a fully fluorinated 
carbon chain (C4–C14) with, for example, a 
terminal sulfonate or carboxylate functional 
group. The environmental presence of PFAAs 
may be a consequence of emissions during 
manufacturing, use, or disposal of products 
(direct sources) as well as transformation of 
other precursors to PFAAs (indirect sources) 
(Armitage et al. 2009; D’eon and Mabury 
2011). The two PFAAs most widely detected 
in humans are the C8-backbone derivatives 
perfluorooctanoate (PFOA) and perfluoro-
octane sulfonate (PFOS), with estimated 
elimination half-lives of around 4 and 5 years, 
respectively (Olsen et al. 2007).
After reports of global contamination, 
phaseout of C8-derivatives was initiated in 
the year 2000 by the major U.S. manufactur-
ers (U.S. Environmental Protection Agency 
2010). This has resulted in decreased human 
exposure compared with peak levels in Europe 
and the United States (Haug et al. 2009b; 
Olsen et al. 2011). However, recent findings 
from the Health and Nutrition Examination 
Survey (NHANES) indicate that PFOA levels 
in the United states remained relatively stable 
between 2003 and 2008, suggesting contin-
ued direct and indirect sources of human 
exposures to PFOA (Kato et al. 2011).
PFAAs accumulate primarily via binding 
to albumin in blood (D’eon et al. 2010; Jones 
et al. 2003), and they are readily transported 
across the placenta (Monroy et al. 2008). 
PFAAs are found in highest concentrations 
in the liver (Hundley et al. 2006; Maestri 
et al. 2006) and low-dose human exposures to 
PFOA and PFOS have been associated with 
modest increases in liver enzymes (Lin et al. 
2010) and blood lipids (Nelson et al. 2010) in 
cross-sectional settings. The relevance of these 
findings is uncertain, however, because prospec-
tive studies have not been conducted. Findings 
from animal studies suggest that PFAAs may 
act as endocrine disruptors, affecting circulating 
estrogens levels through pathways such as aro-
matase induction in the liver (Liu et al. 1996) 
or through altering estrogen-expressive genes 
(Shi et al. 2009), although findings with respect 
to interactions with estrogen receptors have 
not been consistent (Benninghoff et al. 2011; 
Ishibashi et al. 2007).
Experimental studies have demonstrated 
that in utero exposures to certain endocrine 
disruptors, including xenoestrogens, may lead 
to permanent changes in metabolic path-
ways that regulate body weight (Newbold 
et al. 2008). A recent study using a CD-1 
mouse model observed higher body weight 
and increased insulin and leptin levels in 
post  pubertal female offspring after low-dose 
in utero exposures to PFOA (Hines et al. 
2009). The aim of this study was to explore 
these findings in environmentally exposed 
pregnant women with prospective offspring 
follow-up at 20 years of age.
Methods
The birth cohort. Between April 1988 and 
January 1989, 965 women with singleton 
pregnancies were recruited for a birth cohort 
study in Aarhus, Denmark (Olsen et al. 
1995). This was 80% of a consecutive sample 
of 1,212 women attending a midwife center in 
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Ba c k g r o u n d: Perfluoroalkyl acids are persistent compounds used in various industrial   applications. 
Of these compounds, perfluorooctanoate (PFOA) is currently detected in humans worldwide. A 
recent study on low-dose developmental exposure to PFOA in mice reported increased weight and 
elevated biomarkers of adiposity in postpubertal female offspring. 
oB j e c t i v e: We examined whether the findings of increased weight in postpubertal female mice 
could be replicated in humans.
Me t h o d s : A prospective cohort of 665 Danish pregnant women was recruited in 1988–1989 with 
offspring follow-up at 20 years. PFOA was measured in serum from gestational week 30. Offspring 
body mass index (BMI) and waist circumference were recorded at follow-up (n = 665), and bio-
markers of adiposity were quantified in a subset (n = 422) of participants.
re s u l t s: After adjusting for covariates, including maternal pre  pregnancy BMI, smoking, educa-
tion, and birth weight, in utero exposure to PFOA was positively associated with anthropometry at 
20 years in female but not male offspring. Adjusted relative risks comparing the highest with lowest 
quartile (median: 5.8 vs. 2.3 ng/mL) of maternal PFOA concentration were 3.1 [95% confidence 
interval (CI): 1.4, 6.9] for overweight or obese (BMI ≥ 25 kg/m2) and 3.0 (95% CI: 1.3, 6.8) for 
waist circumference > 88 cm among female offspring. This corresponded to estimated increases of 
1.6 kg/m2 (95% CI: 0.6, 2.6) and 4.3 cm (95% CI: 1.4, 7.3) in average BMI and waist circumfer-
ence, respectively. In addition, maternal PFOA concentrations were positively associated with serum 
insulin and leptin levels and inversely associated with adiponectin levels in female offspring. Similar 
associations were observed for males, although point estimates were less precise because of fewer 
observations. Maternal perfluorooctane sulfonate (PFOS), perfluorooctane sulfonamide (PFOSA), 
and perfluorononanoate (PFNA) concentrations were not independently associated with offspring 
anthropometry at 20 years.
co n c l u s i o n s: Our findings on the effects of low-dose developmental exposures to PFOA are in line 
with experimental results suggesting obesogenic effects in female offspring at 20 years of age.
key w o r d s : offspring obesity, overweight, perfluoroalkyl compounds, PFOA, pregnancy, prenatal 
exposure. Environ Health Perspect 120:668–673 (2012).  http://dx.doi.org/10.1289/ehp.1104034 
[Online 3 February 2012]Prenatal exposure to PFOA and offspring overweight
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the city, covering a well-defined geographical 
area. A face-to-face interview was conducted 
at a routine midwife visit in gestational week 
30, covering medical history, anthropometry, 
diet, lifestyle, and socioeconomic factors. A 
blood sample was also collected, and it was 
immediately separated into serum, plasma, 
and erythrocytes and frozen at –20°C. Further 
information on maternal health and birth out-
comes were extracted from hospital records 
and the Danish Medical Birth Registry.
Offspring follow-up. In 2008–2009, study 
mothers and offspring were contacted, and 
offspring were asked to fill out a Web-based 
questionnaire concerning their current health, 
lifestyle, and dietary habits and their current 
height and weight. In addition, a tape measure 
was mailed to all potential participants with 
instructions on how to measure their waist 
circumference. Offspring were also invited to 
participate in a 75–100-min clinical exami-
nation, which included standardized anthro-
pometric measures and collection of a fasting 
blood sample that was immediately centrifuged 
and frozen at –80°C. The study was approved 
by the Danish Data Protection Agency and 
the Danish Council of Ethics (reference no. 
20070157), and all participants gave written 
consent prior to inclusion into the study.
Mother–offspring pairs available for 
analysis. A total of 915 offspring of the 
965 women with singleton pregnancies 
recruited in 1988–1999 were located and con-
tacted in 2008–2009, and 692 of the offspring 
agreed to participate in the follow-up study. 
Missing values on offspring anthropometry 
(n = 4) and maternal blood samples (n = 23) 
left 665 mother–  offspring pairs, or 69% of 
the original cohort, available for analyses. 
Of the 665 offspring included in this study, 
423 (44% of the original cohort) attended the 
clinical examination, and 242 completed the 
Web-based questionnaire only.
Maternal PFAA samples. Serum samples 
from gestational week 30 were measured at 
the Department of Analytical Chemistry at the 
Norwegian Institute of Public Health in Oslo. 
The analytical procedure and sources of chemi-
cals used have been described in detail else-
where (Haug et al. 2009a). Nineteen PFAAs 
were analyzed, and 12 were above the limit of 
quantification (LOQ; 0.05 ng/mL serum for all 
PFAAs reported in this study) in one or more 
samples. For quantification of PFOS, the total 
area of the linear and branched isomers was 
integrated. The quality of the analytical pro-
cedure was monitored by analyzing in-house 
quality control samples and human serum 
samples from interlaboratory comparison 
exercises (Institut national de santé publique 
Québec 2009). For the interlaboratory com-
parison exercises, the coefficient of variation for 
PFOA was between 3% and 9%, depending 
on the concentration of the reference sample. 
No traces of PFAAs above LOQ were observed 
in any of the procedural blanks.
Offspring biomarkers of adiposity. In 
short, adiponectin was quantified by a time-
resolved immunofluorometric assay based on 
two antibodies and recombinant human adi-
ponectin (R&D Systems, Abingdon, United 
Kingdom), as previously described (Frystyk 
et al. 2005). Leptin was determined by a time-
resolved immunofluorometric assay based on 
commercial reagents (R&D Systems) using 
recombinant human leptin as the standard; 
otherwise, quantification was carried out 
essentially as for adiponectin (Frystyk et al. 
2005). Plasma insulin concentrations were 
determined by the commercial Insulin ELISA 
kit (Dako, Copenhagen, Denmark).
Outcome measures. Body mass index 
(BMI) and waist circumference measures 
from the clinical examination were used when 
available (n = 423). Self-reported measures 
from the Web-based questionnaire were used 
for the remaining 242 subjects. Although sub-
jects tend to underestimate their weight by 
self-report (Tokmakidis et al. 2007), relative 
ranks appeared to be retained, as the corre-
lation between measured and self-reported 
BMI was 0.91 for both sexes (Spearman r, 
n = 423). Use of self-reported measures does, 
however, result in underestimation of cases 
when dichotomizing subjects as overweight 
and obese (BMI ≥ 25 kg/m2). In our data 
the sensitivity coefficient and specificity coef-
ficients were 0.46 and 0.99, respectively, for 
identifying overweight and obese female off-
spring based on self-report. The correspond-
ing numbers were 0.63 and 0.98 for male 
offspring, respectively.
Statistical analyses. The mean and SD 
were used to describe normal variables, 
whereas median and interquartile range (IQR) 
were used for skewed variables. Student t-tests 
or chi-square tests were used to test depar-
tures from the null hypothesis for normal 
outcomes, and the Kruskal–Wallis test was 
used for skewed outcomes. Linear regres-
sion was used for continuous outcomes. For 
dichotomous outcomes, relative risk (RR) was 
estimated using log-Poisson regression with 
robust variance estimation, as implemented 
in PROC GENMODE in SAS (version 9.2; 
SAS Institute Inc., Cary, NC, USA). All anal-
yses were performed for males and females 
separately. When examining association with 
anthropometric outcomes, maternal PFOA 
concentrations were divided into quartiles and 
a test for linear trend was performed by using 
the ordinal values. For the biomarker analysis, 
PFOA was entered as a continuous variable.
When estimating the association between 
in utero PFOA concentration and offspring 
anthropometry at 20 years of age, we adjusted 
for the following potential confounders iden-
tified a priori: maternal age (continuous, no 
missing); maternal education (elementary 
schooling, high school or technical schooling, 
university education, higher academic educa-
tion, other education, 6% missing); maternal 
smoking (never, < 10 and ≥ 10 cigarettes/day, 
6% missing); pre  pregnancy BMI [restricted 
cubic spline regression (Durrleman and 
Simon 1989), 2% missing]; parity (0, 1, ≥ 2, 
no missing); infant birth weight (continuous, 
0.2% missing); and offspring age at follow-up 
(continuous, 1% missing). A total of 67 sub-
jects (10%) had missing values for one or 
more of the covariates included. Maternal 
age and parity were included because they 
are known predictors of PFAA exposure (Fei 
et al. 2007). Maternal education and smok-
ing were included to account for potential 
social and lifestyle confounding. Pre  pregnancy 
BMI and birth weight were included because 
they are known predictors of offspring BMI 
(Reynolds et al. 2010). Missing covariate val-
ues were substituted using multiple imputa-
tion, as implemented in PROC MI in SAS 
(SAS Institute, Inc.). 
Because of skewed distributions, offspring 
biomarkers of adiposity were log-transformed 
when examining their association with mater-
nal PFOA concentrations, and estimates were 
adjusted for offspring age and timing of blood 
sample collection.
Results
Non  significant differences in maternal PFOA 
concentration, prepregnancy BMI, and parity 
were observed between mothers whose off-
spring did not participate in follow-up, moth-
ers whose offspring completed the Web-based 
questionnaire only, and mothers whose off-
spring participated in the clinical examination 
(Table 1). However, mothers whose offspring 
did not participate in follow-up were more 
likely to smoke during pregnancy. Females 
who participated in clinical examination 
had significantly lower BMI (≈ 0.8 kg/m2) 
compared with those who completed the 
Web-based questionnaire only, whereas non-
significant differences were observed for waist 
circumference and current smoking. Male 
offspring who participated in the clinical 
examination were not significantly different 
from those who completed the Web-based 
questionnaire only with regard to BMI, waist 
circumference, and current smoking.
The median maternal PFOA serum con-
centration was 3.7 ng/mL (range: 0.1–19.8). 
Maternal PFOS, perfluorooctane sulfonamide 
(PFOSA), and perfluorononanoate (PFNA) 
concentrations increased across quartiles of 
PFOA concentration (Table 2). Eight other 
PFAAs were quantified but were not included 
in analyses because concentrations were low 
(median: ≤ 0.4 ng/mL) and were within a 
narrow range (IQR < 0.2 ng/mL). Mothers in 
the highest quartile of PFOA concentration Halldorsson et al.
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were less likely to be parous (32% vs. 58%) 
and were younger (28.7 vs. 29.8 years) than 
mothers in the lowest quartile of PFOA when 
enrolled into the original study.
The prevalence of overweight or obesity 
(BMI ≥ 25 kg/m2) was similar between male 
and female offspring (19% and 18%, respec-
tively), but waist circumference above action 
level II (Lean et al. 1995) was less common in 
males (3.5% > 102 cm) than in females (16.2% 
> 88 cm) (Table 3). All males and 70% of 
females with waist circumference above action 
level II were overweight or obese. Females were 
more likely than males to report that they were 
currently on a diet (17% vs. 6%).
Maternal PFOA concentrations were posi-
tively associated (p for trend < 0.05) with BMI 
and waist circumference among female off-
spring at 20 years of age (n = 345) in both 
unadjusted and covariate-adjusted analyses 
(Table 4). In adjusted analyses, female offspring 
whose mothers were in the highest quartile 
of PFOA concentration had 1.6 kg/m2 [95% 
confidence interval (CI): 0.6, 2.6] higher BMI 
and 4.3 cm (95% CI: 1.4, 7.3) higher waist 
circumference compared with offspring whose 
mothers were in the lowest quartile. No sta-
tistically significant associations were observed 
for males (p for trend > 0.05, n = 320). Female 
offspring of mothers in the highest versus low-
est PFOA quartile were also more likely to be 
overweight [RR = 3.1 (95% CI: 1.4, 6.9)] and 
to have a waist circumference above action 
level II at 20 years of age [3.0 (95% CI: 1.3, 
6.8)] (Table 5). PFOA was not associated with 
overweight in male offspring, and RR estimates 
were consistently null. Only 11 of 320 male 
offspring had a waist circumference above 
action level II; consequently, RR estimates were 
unstable with wide CIs.
Among female participants who pro-
vided a blood sample at clinical examination 
(n = 252), maternal PFOA concentration was 
positively associated with insulin, leptin, and 
the leptin-adiponectin ratio and inversely 
associated with adiponectin levels (Table 6). 
The associations corresponded to a 2–7% 
change in these biomarkers per 1-unit increase 
in PFOA. Point estimates were similar for 
male offspring but non  significant (n = 170). 
Although the precision of the estimated asso-
ciations between maternal PFOA and the 
biomarkers was reduced because of the small 
sample size for this analysis (particularly in 
males), associations between maternal PFOA 
and offspring anthropometry were compa-
rable with those for the follow-up participants 
as a whole, supporting the validity of these 
estimates. For example, estimated increases in 
BMI comparing highest with lowest quartile of 
maternal PFOA concentration were 1.8 kg/m2 
(95% CI: 0.6, 3.0) and 0.6 kg/m2 (95% CI: 
–0.7, 1.9) for female and male offspring who 
provided a blood sample at clinical examina-
tion, compared with 1.6 kg/m2 (95% CI: 0.6, 
2.6) and 0.6 kg/m2 (95% CI: –0.3, 1.5) for all 
female and male participants, respectively.
Concerning other PFAAs, we observed 
that PFOS, PFNA, and PFOSA (continuous 
variables) were in univariate analysis either 
borderline (p for trend = 0.05 for PFOSA) or 
significantly (p for trend < 0.05 for PFNA, 
Table 1. Maternal and offspring characteristics at baseline and follow-up according to level of participation.
Characteristics
Offspring not 
in follow-up
Offspring only filling out 
Web-based questionnaire
Offspring participating 
in clinical examination p-Value
Maternal n = 209 n = 242 n = 423
PFOA (ng/mL)a 3.7 (1.8) 3.7 (2.0) 3.7 (2.0) 0.68b
Prepregnancy BMI (kg/m2) 21.8 ± 3.8 21.1 ± 2.5 21.4 ± 3.0 0.06c
Nulliparous (%) 54 57 59 0.42d
Smoking during pregnancy (%) 49 36 37 0.01d
Male offspring at follow-up n = 150 n = 170
BMI (kg/m2)e 22.7 ± 2.9 22.6 ± 2.9 0.62c
Waist circumference (cm)e 85.5 ± 10.6 83.5 ± 8.9 0.08c
Current smoker (%) 19 18 0.75d
Female offspring at follow-up n = 92 n = 253
BMI (kg/m2)e 22.3 ± 3.2 21.5 ± 3.0 0.03c
Waist circumference (cm)e 79.8 ± 10.2 78.6 ± 9.7 0.32c
Current smoker (%) 21 17 0.45d
Based on the 874 mothers whose blood samples were analyzed for PFAAs in the Aarhus Birth Cohort (1988–1989). Values 
are median (IQR) for maternal PFOA concentration; otherwise, they are mean ± SD or %. 
aMaternal serum from gestational week 30. bKruskal–Wallis test of differences among participation groups. cF-test (type 
III) of differences among participation groups. dChi-square test of differences among participation groups. eComparison 
for offspring anthropometry is based on self-reported values.
Table 2. Maternal characteristics during pregnancy among 665 participants from the Aarhus Birth Cohort 
(1988–1989).
Quartiles of maternal PFOA concentration
Variables Overall 1 2 3 4 p-Value
Serum concentration (ng/mL) a
PFOA 3.7 (2.0) 2.4 (0.6) 3.3 (0.4) 4.2 (0.5) 5.8 (1.9)
PFOS  21.5 (9.1) 16.0 (5.6) 20.2 (5.7) 23.6 (6.8) 28.5 1 (2.1) < 0.0001b
PFOSA 1.1 (1.0) 0.7 (0.5) 1.1 (0.7) 1.3 (0.9) 1.5 (1.1) < 0.0001b
PFNA 0.3 (0.2) 0.3 (0.2) 0.3 (0.2) 0.4 (0.2) 0.4 (0.3) < 0.0001b
Physical characteristic
Age (years) 29.2 ± 4.1 29.8 ± 3.8 29.2 ± 4.1 28.8 ± 3.9 28.7 ± 4.5 0.01c
Height (cm) 168 ± 6.0 167.4 ± 6.3 167.6 ± 6.5 167.8 ± 5.5 168.0 ± 5.7 0.43c
Prepregnancy BMI (kg/m2) 21.3 ± 2.9 21.1 ± 2.3 21.3 ± 3.2 21.2 ± 2.4 21.5 ± 3.2 0.25c
Birth weight 3.53 ± 0.52 3.62 ± 0.55 3.53 ± 0.57 3.49 ± 0.44 3.47 ± 0.52 0.009c
Smoking during pregnancy (%) 37 40 38 39 31 0.34d
Parous women (%) 42 58 39 38 32 < 0.0001d
Maternal education (%)
Elementary schooling 10 13 12 7 8 0.0002d
High school or technical schooling 23 12 19 25 34
University education 39 44 36 44 32
Higher academic 18 25 20 14 14
Other education or missing 10 6 13 11 12
Values are median (IQR), mean ± SD, or %. 
aBlood (serum) samples were collected in gestational week 30; PFOA, PFNA, PFOS, and PFOSA were detected in all samples. 
bKruskal–Wallis test of differences across quartiles of maternal PFOA concentration. cStudent t-test of differences across 
quartiles of maternal PFOA concentration. dChi-square test of differences across quartiles of maternal PFOA concentration.
Table 3. Characteristics of male and female offspring at 20 years of age (2008–2009), Aarhus Birth Cohort 
(1988–1989).
Characteristic Males Females
Physical characteristic [mean ± SD or n (%)] n = 320 n = 345
Age (years) 19.7 ± 0.4 19.9 ± 0.4
Waist circumference (cm) 84.3 ± 9.3 79.9 ± 9.4
BMI (kg/m2) 22.8 ± 2.9 22.2 ± 3.3
Waist circumference above action level IIa 11 (3.5) 56 (16.2)
Overweight or obeseb 60 (18.9) 61 (17.7)
Subjects in both a) and b) 11 (3.5) 39 (11.3)
Currently on a diet 20 (6.3) 60 (17.4)
Offspring attending clinical examination [median (IQR)] n = 170 n = 252
Insulin (mmol/L) 37 (22) 42 (23)
Leptin (ng/L) 2.2 (3.1) 13.5 (12.6)
Adiponectin (μg/L) 6.8 (3.7) 9.4 (4.5)
Leptin/adiponectin ratio 0.3 (0.6) 1.5 (1.5)
aWaist circumference > 102 cm for males and > 88 cm for females (Lean et al. 1995). bBMI ≥ 25 kg/m2.Prenatal exposure to PFOA and offspring overweight
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PFOS) positively associated with female off-
spring BMI at 20 years. However, after adjust-
ing for PFOA, the regression coefficients 
became non  significant (p for trend ≥ 0.56 in 
all cases, data not shown). We also found no 
evidence that the association between maternal 
PFOA concentration and offspring anthro-
pometry was influenced by the presence of 
the other PFAAs quantified. For example, the 
estimated increase in female offspring BMI 
with a 1-ng/mL increase in maternal PFOA 
in a univariate analysis was 0.43 kg/m2 (95% 
CI: 0.25, 0.60) compared with 0.46 kg/m2 
(95% CI: 0.21, 0.71) based on a model that 
included maternal PFOS, PFOSA, and PFNA 
as continuous terms.
Associations with offspring BMI were 
also stable with respect to maternal parity. 
For female offspring of nulliparous mothers 
(n = 191), we estimated a 0.46-kg/m2 (95% 
CI: 0.27, 0.66) increase in BMI per 1-ng/mL 
increase in PFOA, compared with 0.36 kg/m2 
(95% CI: 0.03, 0.69) for female offspring of 
parous mothers (interaction p-value 0.65).
Discussion
In this cohort of environmentally exposed 
pregnant women, we observed a positive asso-
ciation between in utero exposure to PFOA 
and the prevalence of overweight and a high 
waist circumference among female offspring, 
but not male offspring, at 20 years of age. In 
addition, in utero exposure to PFOA was asso-
ciated with biomarkers of adiposity among 
male and female offspring, although estimates 
for males were not significant.
Animal studies have shown that early-  life 
exposures to xenoestrogens such as diethylstil-
bestrol (Newbold et al. 2008) and bisphenol-A 
(Somm et al. 2009) can lead to permanent dis-
ruption in endocrine functions that regulate 
adiposity. One observation from these studies 
is that low-dose exposures may result in sig-
nificant weight changes in the exposed animals 
only after adult age is reached, whereas a pat-
tern of reduced weight in early infancy followed 
by rapid catch-up growth is often observed at 
higher doses (Newbold et al. 2008). Human 
studies have provided some support for these 
findings, including reports of rapid weight gain 
up to 3 years of age after in utero exposures to 
polychlorinated biphenyls (Verhulst et al. 2009) 
as well as increased overweight at 6 years of age 
after in utero exposure to hexachloro  benzene 
(Smink et al. 2008). However, metabolic path-
ways that might explain these findings are not 
well characterized, and long-term follow-up 
studies have not been conducted.
Indications that environmental expo-
sures to PFAAs may affect cardiometabolic 
risk factors have, so far, been obtained from 
cross-sectional studies focusing on end points 
such as blood lipids (Nelson et al. 2010) and 
glucose homeostasis (Lin et al. 2009), but in 
these studies, findings with respect to anthro-
pometry have been inconsistent. Interpretation 
of cross-sectional findings on anthropometry is 
complex, however, as absorption and distribu-
tion of PFAAs depend on related factors such 
as lean body mass and blood volume (Ahrens 
et al. 2009; Fei et al. 2007).
However, our findings are consistent 
with a recent experimental study on CD-1 
mice that reported increased body weight in 
postpubertal female offspring after low-dose 
(0.01–0.3 mg/kg body weight) in utero 
exposure to PFOA (Hines et al. 2009). In 
that study, increases in weight were most 
pronounced in mid-life and were accompa-
nied by elevated levels of leptin and insu-
lin in the exposed animals. At higher doses 
(≥ 1mg/kg), weight gain was not observed. 
Furthermore, exposing the offspring after 
weaning as opposed to in utero also had no 
effect on weight gain. In at least two animal 
studies, researchers did not observe increased 
body weight after in utero exposure to PFOA 
(Butenhoff et al. 2004; Macon et al. 2011), 
Table 4. Associationsa between in utero exposure to PFOA and the offspring BMI and waist circumference 
at 20 years of age for females (n = 345) and males (n = 320).
PFOA in quartiles 
[median (range)]b
ΔBMI [mean (95% CI)] ΔWaist circumference [mean (95% CI)]
Crude Adjustedc Crude Adjustedc
Females
1 2.3 (0.1–2.8) Referent Referent Referent Referent
2 3.2 (2.8–3.7) 0.2 (–0.7, 1.2) 0.4 (–0.6, 1.3) 1.0 (–1.7, 3.7) 1.4 (–1.4, 4.2)
3 4.2 (3.7–4.8) 0.8 (–0.2, 1.8) 0.9 (–0.1, 1.9) 0.9 (–1.9, 3.6) 1.2 (–1.7, 4.0)
4 5.8 (4.8–19.8) 1.6 (0.6, 2.5) 1.6 (0.6, 2.6) 4.2 (1.5, 6.9) 4.3 (1.4, 7.3)
p-Value for trendd 0.0007 0.001 0.005 0.006
Malese
1 2.4 (1.2–2.8) Referent Referent Referent Referent
2 3.3 (2.8–3.7) 0.5 (–0.4, 1.4) 0.6 (–0.3, 1.5) 1.3 (–1.7, 4.3) 1.3 (–1.5, 4.1)
3 4.2 (3.7–4.8) 0.3 (–0.7, 1.2) 0.2 (–0.7, 1.1) 1.0 (–2.0, 4.0) 1.0 (–1.9, 3.8)
4 5.8 (4.8–16.6) 0.4 (–0.5, 1.3) 0.6 (–0.3, 1.5) 0.7 (–2.2, 3.6) 1.3 (–1.6, 4.1)
p-Value for trendd 0.47 0.30 0.72 0.48
aLinear regression with continuous outcome variables (BMI or waist circumference) and PFOA divided into quartiles. 
bNanograms per milliliter serum. cAdjusted for maternal age, maternal education, maternal pre  prepregnancy BMI, smok-
ing during pregnancy, parity, infant birth weight, and offspring age at follow-up. dStudent’s t-test with PFOA included in 
the regression model as an ordinal variable. eWaist circumference was missing for two male offspring (n = 318).
Table 5. Associationsa between in utero exposure to PFOA and risk of being overweight or having waist 
circumference above action level II at 20 years of age for females (n = 345) and males (n = 320).
PFOA in quartiles 
[median (range)]c
Overweight (BMI ≥ 25 kg/m2)  
[RR (95% CI)]
High waist circumferenceb  
[RR (95% CI)]
Cases/no. Crude Adjustedd Cases/no. Crude Adjustedd
Females
1 2.3 (0.1–2.8) 10/91 1.0 1.0 9/91 1.00 1.0
2 3.3 (2.8–3.7) 12/87 1.3 (0.6, 2.8) 1.5 (0.6, 3.5) 13/87 1.5 (0.7, 3.4) 1.7 (0.7, 4.1)
3 4.2 (3.7–4.8) 15/81 1.7 (0.8, 3.5) 2.0 (0.9, 4.7) 10/81 1.2 (0.5, 2.9) 1.3 (0.5, 3.2)
4 5.8 (4.8–19.8) 24/86 2.5 (1.3, 5.0) 3.1 (1.4, 6.9) 24/86 2.8 (1.4, 5.7) 3.0 (1.3, 6.8)
p-Value for trende 0.007 0.003 0.008 0.01
Malesf
1 2.3 (1.2–2.8) 13/74 1.00 1.00 1/74 1.00 1.00
2 3.3 (2.8–3.7) 17/81 1.2 (0.6, 2.3) 1.2 (0.6, 2.6) 4/81 3.7 (0.4, 32.0) 6.1 (0.4, 90.0)
3 4.3 (3.7–4.8) 14/78 1.0 (0.5, 2.0) 1.0 (0.4, 2.2) 3/77 2.9 (0.3, 27.1) 7.3 (0.4, 121.4)
4 5.8 (4.8–16.6) 16/87 1.0 (0.5, 2.0) 1.1 (0.5, 2.6) 3/86 2.6 (0.3, 24.3) 13.3 (0.4, 298.9)
p-Value for trende 0.97 0.89 0.60 0.11
aLog-Poisson regression with robust variance estimation, as implemented in PROC GENMODE in SAS. bWaist circumfer-
ence > 88 cm for females and > 102 cm for males (Lean et al. 1995). cNanograms per milliliter serum. dAdjusted for mater-
nal age, maternal education, maternal pre  prepregnancy BMI, smoking during pregnancy, parity, infant birth weight, and 
offspring age at follow-up. eChi-square test (Type III) with PFOA included in the regression model as an ordinal variable. 
fWaist circumference was missing for two male offspring (n = 318).
Table 6. Associationa between in utero exposure to PFOA and offspring serum biomarkers of adiposity at 
20 years of age. 
Females (n = 252) Males (n = 170)
Biomarker Percent changeb,c 95% CI p-Value Percent changec 95% CI p-Value
Insulin 4.5 1.8, 7.2 0.001 2.2 –0.8, 5.3 0.15
Leptin 4.8 0.5, 9.4 0.03 4.5 –2.6, 12.1 0.21
Adiponectin –2.3 –4.5, –0.2 0.03 –1.7 –4.6, 1.2 0.25
Leptin/adiponectin ratio 7.2 2.2, 12.5 0.004 6.3 –1.5, 14.6 0.11
The associations are limited to the subgroup of participants (n = 422) that provided blood samples at clinical examination.
aLinear regression using log-transformation for the dependent variable (continuous). The results are adjusted for time of 
blood sample collection (e.g., 08:00–12:30) and offspring age at follow-up. bBlood sample was missing for one female sub-
ject who attended clinical examination. cPercent change in the outcome measure for 1-ng/mL change in serum PFOA.Halldorsson et al.
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but one study used higher doses (≥ 1mg/kg) 
(Butenhoff et al. 2004) and the other followed 
animals only until 12 weeks of age (Macon 
et al. 2011).
Similar to the findings of Hines et al. 
(2009), we observed significant associations 
between maternal PFOA and insulin and lep-
tin in addition to adiponectin levels among 
female offspring. Changes in these biomarkers 
were modest, however, and corresponded to 
what could be expected from the observed 
increase in offspring BMI. The results from 
our biomarker analysis provide valuable 
insight, as elevated insulin levels predict cen-
tral fat in both normal weight and overweight 
women (Carey et al. 1996). Therefore, these 
results provide added weight to our findings, 
as BMI and waist circumference are relatively 
crude measures of body composition.
The absence of an association between 
in utero PFOA exposure and weight gain 
among male offspring is noteworthy but not 
unexpected. Sex-specific differences with 
respect to weight gain have been observed for 
xenoestrogens, where female offspring appear 
to be more affected (Newbold et al. 2008; 
Somm et al. 2009). Results for male offspring 
were not reported in the CD-1 mouse study 
(Hines et al. 2009), and experimental studies 
have suggested that reproductive development, 
but not weight gain, may be a more sensitive 
end point for males with respect to develop-
mental exposures to PFAAs (Shi et al. 2007). 
Despite these observations, results for male off-
spring in our study should be interpreted cau-
tiously, as many study participants were still in 
their late adolescence, and relatively few males 
had high waist circumference compared with 
females. Because girls gain more fat mass and 
boys gain more fat-free mass during adolescent 
age (Ahmed et al. 1999), weight gain in male 
offspring at a later age when accumulation of 
fat mass increases cannot be excluded.
Concerning mechanism, there are at least 
three potential pathways by which in utero 
exposure to PFOA might affect offspring 
weight. First, PFOA may interfere with ovary 
development in utero, leading to impaired 
estrogen synthesis among female offspring. 
This mechanism is supported by the obser-
vation that in utero PFOA exposure did not 
affect weight gain in the previously mentioned 
study on CD-1 mice when ovariectomy was 
performed in exposed offspring after delivery 
(Hines et al. 2009). Second, PFAAs may inter-
act with the peroxisome proliferator-  activated 
receptors (PPAR) PPARα and PPARγ, which 
are involved in lipid metabolism in adipocytes 
(Hines et al. 2009). Whether such an inter-
action can lead to sex-specific differences in 
weight gain remains unclear. Third, thyroid 
hormones might play some role: The results 
of one cross-sectional study suggested that 
PFOA exposure may lead to an increased risk 
of thyroid disease (Melzer et al. 2010), which is 
more common in females than males. A recent 
study from the C8 Health project also observed 
a modest positive association of PFOA with 
serum thyroxine and an inverse association 
with T3 uptake (Knox et al. 2011). The overall 
evidence linking PFAAs to thyroid function 
is still weak (Steenland et al. 2010), particu-
larly as prospective studies have not been con-
ducted, and no clear effect on thyroid function 
has been observed in occupationally exposed 
individuals (Olsen and Zobel 2007).
A unique strength of our study is the long-
term prospective follow-up with outcome 
assessment at an age where weight changes 
due to linear growth have leveled off, and it 
was possible to adjust for several prenatal fac-
tors including maternal BMI, smoking, and 
education. We were also able to support our 
findings on offspring anthropometry with 
assessment on serum biomarkers of adiposity 
in a subset of study participants. Furthermore, 
quantification of a total of 12 PFAAs made it 
possible to conclude that PFAAs other than 
PFOA were unlikely to play an important 
role in our study population, either because 
of a low concentration or a lack of association 
after adjusting for PFOA.
Concerning limitations, we acknowledge 
that uncertainties regarding routes of human 
exposure to PFAAs may have resulted in a 
failure to identify important confounders. We 
also acknowledge that maternal PFOA con-
centrations in late gestation may be influenced 
by factors such as blood volume expansion, 
decreased albumin concentration, and fetal 
uptake (Fei et al. 2007; Frederiksen 2001), 
and these factors may predict fetal outcomes 
such as birth weight (Savitz 2007). However, 
with a temporal separation of 20 years, our 
findings should be less prone to such influence.   
Furthermore, PFOA concentrations in samples 
collected at around gestational weeks 6–12 
and 24 (Olsen et al. 2001) and in cord blood 
have been observed to be highly cor  related 
(r ≈ 0.8–0.9) (Fei et al. 2007).
Finally, as with all longitudinal studies, 
losses during follow-up are inevitable, and this 
is perhaps the main limitation of our study. 
Having quantified maternal PFOA concentra-
tions in 874 (or 72%) of 1,212 women who 
were originally invited to participate, it is reas-
suring that exposure levels were non  differential 
with respect to level of participation in the 
  follow-up study. A higher prevalence of smok-
ing among mothers whose offspring did not 
participate suggests that losses due to follow-up 
were related to some extent to maternal life-
style. There were relatively modest differences 
in anthropometry between offspring who par-
ticipated in the clinical examination and those 
who completed the Web-based questionnaire 
only. Nonetheless, our secondary analyses 
of offspring biomarkers of adiposity may be 
compromised because of the low participation 
rate, particularly among males.
Conclusion
In a cohort of environmentally exposed preg-
nant women, a positive association between 
in utero exposure to PFOA and the prevalence 
of overweight and high waist circumference 
was observed in female offspring at 20 years 
of age. Our findings are in line with recent 
experimental findings (Hines et al. 2009) and 
provide added support for the hypothesis that 
early-life exposure to certain endocrine dis-
ruptors, even at low concentrations, may play 
a role in the current obesity epidemic. Given 
the widespread detection of PFOA in humans 
and wildlife and observed increase in related 
perfluorinated compounds of similar biologi-
cal potential (Harada et al. 2011; Haug et al. 
2009b), it is of considerable public health 
importance to understand and eliminate path-
ways of human exposures to PFAAs.
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